Back to catalogue
APTA
Aptamer Group PLC
410/1000 Overall fit
AI beneficiary 35% 32
Operating leverage 25% 62
Valuation 25% 30
Downside protection 15% 44
First-pass take
Aptamer shows strong operational leverage (40% revenue growth, improving EBITDA trajectory) and validation with tier-1 pharma partners. However, no explicit AI exposure, ongoing losses (£2.4m FY25), material going-concern risk, and no valuation anchor. Licensing portfolio nascent.
Flags
loss-makinggoing-concernmicro-capno-valuation-datadilutive-equityearly-stage